Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

NARecruitingINTERVENTIONAL

Enrollment

204

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2032

Conditions

Hepatocellular CarcinomaAdjuvant Therapy

Interventions

DRUG

Donafenib

Donafenib 100 mg twice daily (BID)

Trial Locations (1)

RECRUITING

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER